Percent of days abstinent · people with anxiety and comorbid alcohol use disorders
1 finding from 1 review
Drinks per drinking day · people with anxiety and comorbid alcohol use disorders
1 finding from 1 review
Depression symptom reduction · people with anxiety and comorbid alcohol use disorders
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with TCAs (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with ABT‐200 (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
It is very uncertain whether fluoxetine changes failure to complete ‐ side effects ‐ compared with phenelzine (very low certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with pramipexole (low certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ total ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with reboxetine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine probably leads to lower failure to complete ‐ total ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with agomelatine (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine probably leads to higher failure to respond (reduction ≥ 50% on HDRS) compared with sertraline (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with sertraline (moderate certainty).
1 finding from 1 review